Last reviewed · How we verify
Bimatoprost Solution 1
At a glance
| Generic name | Bimatoprost Solution 1 |
|---|---|
| Sponsor | Allergan |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- AGN-193408 SR in the Treatment of Open-angle Glaucoma or Ocular Hypertension (PHASE1, PHASE2)
- Study of Corneal Biomechanics in Glaucoma Patients Using Brillouin Microscopy
- Aqueous Humor Dynamics of NCX 470 Ophthalmic Solution (PHASE2, PHASE3)
- Triplenex (triple Fixed Combination) Use Evaluation in Patients with Glaucoma (PHASE4)
- A Randomized, Double-blind, Parallel-group, Two-arm, Multiple Dose, Multicenter, Bioequivalence Study With Clinical Endpoint in the Treatment of Subjects With Chronic Open-angle Glaucoma or Ocular Hypertension in Both Eyes (PHASE1)
- Bioequivalence Study With Clinical Endpoint Comparing Bimatoprost Ophthalmic Solution 0.01% to LUMIGAN® In The Treatment of Chronic Open-Angle Glaucoma (PHASE3)
- Combined CO2 Fractional Laser With Bimatoprost 0.03% Treatment of Alopecia Areata (PHASE1, PHASE2)
- Bioequivalence Study With Clinical Endpoint Comparing Bimatoprost Ophthalmic Solution 0.01% and LUMIGAN® in the Treatment of Chronic Open-Angle Glaucoma or Ocular Hypertension in Both Eyes. (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |